These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 19493069)

  • 21. Patent watch: EPO rejects reach through claims.
    Nat Rev Drug Discov; 2010 Jan; 9(1):12. PubMed ID: 20043023
    [No Abstract]   [Full Text] [Related]  

  • 22. Bioterrorism and patent rights: "compulsory licensure" and the case of Cipro.
    Resnik DB; DeVille KA
    Am J Bioeth; 2002; 2(3):29-39. PubMed ID: 12230852
    [No Abstract]   [Full Text] [Related]  

  • 23. Teva Pharmaceuticals v. Sandoz: availability of generic glatiramer acetate and the impact to patent litigation claim construction.
    Fogel LE; Ray CJ
    Expert Opin Ther Pat; 2015 Jan; 25(1):1-4. PubMed ID: 25363310
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pay drug companies $1bn for each new antibiotic, says report.
    Owen J
    BMJ; 2016 May; 353():i2863. PubMed ID: 27198868
    [No Abstract]   [Full Text] [Related]  

  • 25. International patent protection for HIV-related therapies: patent attorney's perspective.
    Pavento LC; Greene JL; McDonald JK
    Emory Int Law Rev; 2003; 17(2):919-31. PubMed ID: 15199935
    [No Abstract]   [Full Text] [Related]  

  • 26. Patenting bioactive molecules from biodiversity: the Brazilian experience.
    Nogueira RC; de Cerqueira HF; Soares MB
    Expert Opin Ther Pat; 2010 Feb; 20(2):145-57. PubMed ID: 20099999
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Patent watch: Australia's highest court decides isolated nucleic acids are not patent eligible.
    Guerin L; Wickham M
    Nat Rev Drug Discov; 2015 Dec; 14(12):813. PubMed ID: 26567700
    [No Abstract]   [Full Text] [Related]  

  • 28. Antibiotic research and development: business as usual?
    Harbarth S; Theuretzbacher U; Hackett J;
    J Antimicrob Chemother; 2015; 70(6):1604-7. PubMed ID: 25673635
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Needs-driven versus market-driven pharmaceutical innovation: the consortium for the development of a new medicine against malaria in Brazil.
    Kameda K
    Dev World Bioeth; 2014 Aug; 14(2):101-8. PubMed ID: 24761744
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The North American Free Trade Agreement's effect on pharmaceutical patents: a bitter pill to swallow or a therapeutic solution?
    Silbermann JM
    J Contemp Health Law Policy; 1996; 12(2):607-36. PubMed ID: 8666736
    [No Abstract]   [Full Text] [Related]  

  • 31. Incentives aim to boost antibiotic development.
    Roberts JP
    Nat Biotechnol; 2012 Aug; 30(8):735. PubMed ID: 22871701
    [No Abstract]   [Full Text] [Related]  

  • 32. Some questions about the moral responsibilities of drug companies in developing countries.
    Brock DW
    Dev World Bioeth; 2001 May; 1(1):33-7. PubMed ID: 12870506
    [No Abstract]   [Full Text] [Related]  

  • 33. Compulsory licensing in Canada and Thailand: comparing regimes to ensure legitimate use of the WTO rules.
    Lybecker KM; Fowler E
    J Law Med Ethics; 2009; 37(2):222-39. PubMed ID: 19493068
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Impact of economic, regulatory, and patent policies on innovation in cancer chemoprevention.
    Grabowski HG; Moe JL
    Cancer Prev Res (Phila); 2008 Jul; 1(2):84-90. PubMed ID: 19138940
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Do cost-sharing and entry deregulation curb pharmaceutical innovation?
    Grossmann V
    J Health Econ; 2013 Sep; 32(5):881-94. PubMed ID: 23896384
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Report urges controversial 'delinkage' to foster new antibiotics.
    Holmes D
    Nat Med; 2014 Apr; 20(4):320. PubMed ID: 24710363
    [No Abstract]   [Full Text] [Related]  

  • 37. Is India ready to lead the battle for fair access to medicines?
    Lancet Oncology
    Lancet Oncol; 2013 May; 14(6):437. PubMed ID: 23639313
    [No Abstract]   [Full Text] [Related]  

  • 38. Can open-source drug R&D repower pharmaceutical innovation?
    Munos B
    Clin Pharmacol Ther; 2010 May; 87(5):534-6. PubMed ID: 20407458
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Patent necessity: intellectual property dilemmas in the biotech domain and treatment equity for developing countries.
    Spectar JM
    Houst J Int Law; 2002; 24(2):227-78. PubMed ID: 16189914
    [No Abstract]   [Full Text] [Related]  

  • 40. Is Canada patent deal obstructing Ebola vaccine development?
    Attaran A; Nickerson JW
    Lancet; 2014 Nov; 384(9958):e61. PubMed ID: 25467593
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.